XTX Topco Ltd Buys Shares of 18,716 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

XTX Topco Ltd bought a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 18,716 shares of the company’s stock, valued at approximately $222,000.

A number of other large investors have also recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Nurix Therapeutics by 13.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,829 shares of the company’s stock worth $224,000 after acquiring an additional 2,260 shares during the last quarter. ARK Investment Management LLC raised its position in Nurix Therapeutics by 4.0% during the 1st quarter. ARK Investment Management LLC now owns 1,590,910 shares of the company’s stock worth $18,900,000 after purchasing an additional 60,617 shares during the last quarter. TD Asset Management Inc raised its position in Nurix Therapeutics by 8.1% during the 1st quarter. TD Asset Management Inc now owns 42,420 shares of the company’s stock worth $504,000 after purchasing an additional 3,186 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Nurix Therapeutics during the 1st quarter worth $224,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Nurix Therapeutics during the 1st quarter worth $374,000.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NRIX. UBS Group lowered their price objective on Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday, July 10th. Needham & Company LLC reissued a “buy” rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Stephens reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Nurix Therapeutics in a research report on Thursday, July 10th. Morgan Stanley set a $16.00 target price on Nurix Therapeutics and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Finally, Wall Street Zen raised Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 21st. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $28.87.

Nurix Therapeutics Price Performance

Shares of NRIX stock opened at $10.02 on Wednesday. The company has a market capitalization of $766.03 million, a P/E ratio of -3.84 and a beta of 2.14. The company’s 50-day simple moving average is $11.77 and its two-hundred day simple moving average is $12.58. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Wednesday, July 9th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.27. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. The business had revenue of $44,056 billion for the quarter, compared to the consensus estimate of $16.26 million. On average, research analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Buying and Selling

In other Nurix Therapeutics news, insider Gwenn Hansen sold 4,308 shares of the firm’s stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total value of $51,739.08. Following the completion of the transaction, the insider owned 69,023 shares of the company’s stock, valued at approximately $828,966.23. This trade represents a 5.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Houte Hans Van sold 5,402 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $11.03, for a total transaction of $59,584.06. Following the transaction, the chief financial officer directly owned 35,512 shares of the company’s stock, valued at approximately $391,697.36. This trade represents a 13.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,014 shares of company stock valued at $163,014 in the last three months. 7.40% of the stock is currently owned by corporate insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.